aTyr Pharma, Inc. (LIFE)
Market Cap | 114.80M |
Revenue (ttm) | 10.39M |
Net Income (ttm) | -45.34M |
Shares Out | 53.16M |
EPS (ttm) | -1.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 197,607 |
Open | 2.13 |
Previous Close | 2.11 |
Day's Range | 2.12 - 2.24 |
52-Week Range | 1.82 - 5.97 |
Beta | 1.23 |
Analysts | Buy |
Price Target | 19.53 (+804.17%) |
Earnings Date | May 8, 2023 |
About LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for LIFE stock is "Buy." The 12-month stock price forecast is $19.53, which is an increase of 804.17% from the latest price.
News

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT. Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT.

Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan.

aTyr Pharma to Present at March Investor Conferences
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA...

Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

aTyr Pharma Announces Commencement of Public Offering of Common Stock
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA ...

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care. Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of ca...

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis
Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA ...

Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment.

aTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA ...

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST

aTyr Pharma to Present at the Jefferies London Healthcare Conference
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA ...

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
Collaboration aims to accelerate drug discovery and advance company's tRNA synthetase platform Collaboration aims to accelerate drug discovery and advance company's tRNA synthetase platform

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
Compositions and methods patent covers antibodies targeting NRP2 which may have therapeutic applications in the areas of cancer and inflammation Compositions and methods patent covers antibodies targe...

aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRN...

aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis.

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmo...

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair.

aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
Conference hosted by The Ohio State University's Center for RNA Biology to showcase latest advancements in tRNA biology Conference hosted by The Ohio State University's Center for RNA Biology to showc...

aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synt...

Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May.